Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients
Type 2 diabetes is often associated with arterial atherosclerosis in large blood vessels. We set out to elucidate whether commonly used antidiabetic drugs metformin, sitagliptin, and pioglitazone will reduce atherosclerosis in T2DM patients. We enrolled 176 individuals with type 2 diabetes, which we...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2017/5032708 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849700037113675776 |
|---|---|
| author | Xiaojie Liu Tao Mei Wei Chen Shandong Ye |
| author_facet | Xiaojie Liu Tao Mei Wei Chen Shandong Ye |
| author_sort | Xiaojie Liu |
| collection | DOAJ |
| description | Type 2 diabetes is often associated with arterial atherosclerosis in large blood vessels. We set out to elucidate whether commonly used antidiabetic drugs metformin, sitagliptin, and pioglitazone will reduce atherosclerosis in T2DM patients. We enrolled 176 individuals with type 2 diabetes, which were divided into four treatment groups according to different oral drugs: metformin alone, sitagliptin alone, pioglitazone alone, or combination of metformin and sitagliptin. We assessed changes in glycometabolism, lipid metabolism, cytokine released, and carotid artery intima-media thickness as the readout for improvement in atherosclerosis. HbA1c levels were significantly decreased in all treatment groups (p<0.05), and FBG levels were also decreased in metformin and combined groups (p<0.05). In addition, we found IL-6 levels significantly decreased in all treatment groups (p<0.05). Treatment with pioglitazone showed a significant increase in BMI, HDL, and ADPN levels (p<0.05). We also observed a significant decrease in NHDL levels in the combined treatment group (p<0.05). Our data revealed that in addition to hypoglycemic properties of metformin, sitagliptin, and pioglitazone, these drugs also have the potential to promote an anti-inflammatory response. Therefore, combination therapy may be more beneficial for reducing atherosclerosis in patients with type 2 diabetes. The clinical trial is registered with ChiCTR-ORC-17010835. |
| format | Article |
| id | doaj-art-30f8febc8d3a4f0a86bb9a023d0d86e6 |
| institution | DOAJ |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-30f8febc8d3a4f0a86bb9a023d0d86e62025-08-20T03:18:24ZengWileyMediators of Inflammation0962-93511466-18612017-01-01201710.1155/2017/50327085032708Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM PatientsXiaojie Liu0Tao Mei1Wei Chen2Shandong Ye3School of Medicine, Shandong University, Jinan, Shandong, ChinaDepartment of MEC, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, ChinaDepartment of Nephrology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, ChinaSchool of Medicine, Shandong University, Jinan, Shandong, ChinaType 2 diabetes is often associated with arterial atherosclerosis in large blood vessels. We set out to elucidate whether commonly used antidiabetic drugs metformin, sitagliptin, and pioglitazone will reduce atherosclerosis in T2DM patients. We enrolled 176 individuals with type 2 diabetes, which were divided into four treatment groups according to different oral drugs: metformin alone, sitagliptin alone, pioglitazone alone, or combination of metformin and sitagliptin. We assessed changes in glycometabolism, lipid metabolism, cytokine released, and carotid artery intima-media thickness as the readout for improvement in atherosclerosis. HbA1c levels were significantly decreased in all treatment groups (p<0.05), and FBG levels were also decreased in metformin and combined groups (p<0.05). In addition, we found IL-6 levels significantly decreased in all treatment groups (p<0.05). Treatment with pioglitazone showed a significant increase in BMI, HDL, and ADPN levels (p<0.05). We also observed a significant decrease in NHDL levels in the combined treatment group (p<0.05). Our data revealed that in addition to hypoglycemic properties of metformin, sitagliptin, and pioglitazone, these drugs also have the potential to promote an anti-inflammatory response. Therefore, combination therapy may be more beneficial for reducing atherosclerosis in patients with type 2 diabetes. The clinical trial is registered with ChiCTR-ORC-17010835.http://dx.doi.org/10.1155/2017/5032708 |
| spellingShingle | Xiaojie Liu Tao Mei Wei Chen Shandong Ye Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients Mediators of Inflammation |
| title | Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients |
| title_full | Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients |
| title_fullStr | Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients |
| title_full_unstemmed | Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients |
| title_short | Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients |
| title_sort | comparison of antidiabetic medications during the treatment of atherosclerosis in t2dm patients |
| url | http://dx.doi.org/10.1155/2017/5032708 |
| work_keys_str_mv | AT xiaojieliu comparisonofantidiabeticmedicationsduringthetreatmentofatherosclerosisint2dmpatients AT taomei comparisonofantidiabeticmedicationsduringthetreatmentofatherosclerosisint2dmpatients AT weichen comparisonofantidiabeticmedicationsduringthetreatmentofatherosclerosisint2dmpatients AT shandongye comparisonofantidiabeticmedicationsduringthetreatmentofatherosclerosisint2dmpatients |